Literature DB >> 15086519

The cloning and characterization of a second brain enzyme with NAAG peptidase activity.

Tomasz Bzdega1, Samantha L Crowe, Epolia R Ramadan, Kathryn H Sciarretta, Rafal T Olszewski, Olumide A Ojeifo, Victoria A Rafalski, Barbara Wroblewska, Joseph H Neale.   

Abstract

The peptide neurotransmitter N-acetylaspartylglutamate is inactivated by extracellular peptidase activity following synaptic release. It is speculated that the enzyme, glutamate carboxypeptidase II (GCPII, EC 3.14.17.21), participates in this inactivation. However, CGCPII knockout mice appear normal in standard neurological tests. We report here the cloning and characterization of a mouse enzyme (tentatively identified as glutamate carboxypeptidase III or GCPIII) that is homologous to an enzyme identified in a human lung carcinoma. The mouse peptidase was cloned from two non-overlapping EST clones and mouse brain cDNA using PCR. The sequence (GenBank, AY243507) is 85% identical to the human carcinoma enzyme and 70% homologous to mouse GCPII. GCPIII sequence analysis suggests that it too is a zinc metallopeptidase. Northern blots revealed message in mouse ovary, testes and lung, but not brain. Mouse cortical and cerebellar neurons in culture expressed GCPIII message in contrast to the glial specific expression of GCPII. Message levels of GCPIII were similar in brains obtained from wild-type mice and mice that are null mutants for GCPII. Chinese hamster ovary (CHO) cells transfected with rat GCPII or mouse GCPIII expressed membrane bound peptidase activity with similar V(max) and K(m) values (1.4 micro m and 54 pmol/min/mg; 3.5 micro m and 71 pmol/min/mg, respectively). Both enzymes are activated by a similar profile of metal ions and their activities are blocked by EDTA. GCPIII message was detected in brain and spinal cord by RT-PCR with highest levels in the cerebellum and hippocampus. These data are consistent with the hypothesis that nervous system cells express at least two differentially distributed homologous enzymes with similar pharmacological properties and affinity for NAAG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086519     DOI: 10.1111/j.1471-4159.2004.02361.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  23 in total

1.  Molecular characterization of N-acetylaspartylglutamate synthetase.

Authors:  Ivonne Becker; Julia Lodder; Volkmar Gieselmann; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

2.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI.

Authors:  Jun-Feng Feng; Ken C Van; Gene G Gurkoff; Christina Kopriva; Rafal T Olszewski; Minsoo Song; Shifeng Sun; Man Xu; Joseph H Neale; Po-Wai Yuen; David A Lowe; Jia Zhou; Bruce G Lyeth
Journal:  Brain Res       Date:  2011-04-20       Impact factor: 3.252

Review 4.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Authors:  Mindy I Davis; Melanie J Bennett; Leonard M Thomas; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

Review 6.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

Review 7.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

8.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

9.  Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.

Authors:  Rafal T Olszewski; Marta M Wegorzewska; Ana C Monteiro; Kristyn A Krolikowski; Jia Zhou; Alan P Kozikowski; Katrice Long; John Mastropaolo; Stephen I Deutsch; Joseph H Neale
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

10.  The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes.

Authors:  Karolina Kolodziejczyk; Nicola B Hamilton; Anna Wade; Ragnhildur Káradóttir; David Attwell
Journal:  Brain       Date:  2009-04-21       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.